The emerging role of estrogen related receptorα in complications of non-small cell lung cancers (Review)

TAPAN K. MUKHERJEE1-3, PARTH MALIK4 and JOHN R. HOIDAL1-3

1Division of Respiratory, Critical Care and Occupational Pulmonary Medicine and 2Department of Internal Medicine, University of Utah; 3George E. Wahlen Department of Veterans Affairs Medical Centre, Salt Lake City, UT 84132, USA; 4School of Chemical Sciences, Central University of Gujarat, Gandhinagar, Gujarat 382030, India

Received July 6, 2020; Accepted November 18, 2020

DOI: 10.3892/ol.2021.12519

Abstract. Approximately 85% of lung cancer cases are recognized as non-small cell lung cancer (NSCLC) with a perilous (13-17%) 5-year survival in Europe and the USA. Although tobacco smoking has consistently emerged as the leading cause of NSCLC complications, its consequences are distinctly manifest with respect to sex bias, due to differential gene and sex hormone expression. Estrogen related receptor α (ERRα), a member of the nuclear orphan receptor superfamily is normally expressed in the lungs, and activates various nuclear genes without binding to the ligands, such as estrogens. In NSCLC ERRα expression is significantly higher compared with healthy individuals. It is well established ERα and ERβ, have 93% and 60% identity in the DNA and ligand binding domains, respectively. ERα and ERRα have 69% (70% with ERRα-1) and 34% (35% with ERRα-1) identity, respectively; ERRα and ERRβ, have 92 and 61% identity, respectively. However, whether there is distinctive ERRα interaction with mammalian estrogens or concurrent involvement in non-ER signalling pathway activation is not known. Relevant to NSCLC, ERRα promotes proliferation, invasion and migration by silencing the tumor suppressor proteins p53 and pRB, and accelerates G2-M transition during cell division. Epithelial to mesenchymal transition (EMT) and activation of Slug (an EMT associated transcription factor) are the prominent mechanisms by which ERRα activates NSCLC metastasis. Based on these observations, the present article focuses on the feasibility of antiERRα as a therapeutic strategy for NSCLC complications.

Correspondence to: Dr Tapan K. Mukherjee, Division of Respiratory, Critical Care and Occupational Pulmonary Medicine, Wintrobe Building, University of Utah, Salt Lake City, UT 84132, USA; E-mail: tapan400@gmail.com

Abbreviations: ERR, estrogen related receptor; ERs, estrogen receptors; NSCLC, non-small cell lung cancer; EMT, epithelial to mesenchymal transition; CD, cluster of differentiation; MMP, matrix metalloproteinase; PAI, plasminogen activator inhibitor; PThRP, parathyroid hormone-related protein; EGFR, epidermal growth factor receptor; ELK, Ets like transcription factor-1; KRAS, Kirsten rat sarcoma viral oncogene homolog; ALK, anaplastic lymphoma kinase; CYP, cytochrome P450; PD1, programmed cell death protein 1; GSTM1, glutathione S-transferase Mu 1; cDNA, complementary DNA; GRIP1, glutamate receptor-interacting protein 1; PR, progesterone; HER, human epidermal growth factor receptor-2; NR3B, nuclear receptor 3B; ESRRA, estrogen related receptor; ESRRB, estrogen related receptorβ; ESRRG, estrogen related receptorγ; NTD, N-terminal domain; DBD, DNA binding domain; LBD, ligand binding domain; NR, nuclear receptors; ERRE, ERR response element; HDAC8, histone deacetylase; SIRT1, sirtuin 1; PCAF, P300/CBP associated factor; ERE, estrogen response element; SP-1, specificity protein-1; AP-1, activator protein-1; AF, activation function; PPARγ, peroxisome proliferator-activated receptor γ; PGC-1, proliferator activated receptor γ co-activator-1; KO, knockout; LUAD, lung adenocarcinoma; ROS, reactive oxygen species; LSCC, lung squamous cell carcinoma; PTEN, phosphate and tensin homolog; MAPK, mitogen activated protein kinase; PI3K, phosphoinositide 3-Kinase; ZEB1, zinc finger E-box-binding homeobox 1; IL-10, interleukin-10; TGF-β, tumor growth factor-β; CTLA4, cytotoxic T-lymphocyte associated protein 4; TIM-3, T-Cell immunoglobulin and mucin domain-3; DES, diethylstilbestrol; SERT, selective estrogen receptor modulators; SERDs, selective estrogen receptor downregulators;

Key words: estrogens, non-small cell lung cancer, estrogen receptors, estrogen related receptor alpha, cell cycle, epithelial mesenchymal transition

Contents
1. Introduction
2. ERRs and their physiological functions
3. ERRs in NSCLCs
4. Role of ERR-α in cell cycle regulation and NSCLC proliferation
5. Role of ERR-α in the invasion and migration of NSCLC cells
6. Conclusions and future perspective

1. Introduction

Non-small cell lung cancer (NSCLC) is one of the most prevalent malignant tumors and accounts for ~85% of the lung cancer related deaths globally (1). As reported in 2017, lung cancer related deaths in Europe were the leading cause of
cancer deaths in both sexes, accounting for 24% male deaths and 15% female deaths (2,3). Data from 2017 predicted a 10.7% fall in 5 years for males (corresponding to 33.3 deaths per one lakh residents), individuals for females a 5.1% increment (accounting for 14.6 deaths per one lakh individuals) (1-3). Unfortunately, current therapies against NSCLCs are ineffective due to the advanced stage tumour progression at diagnosis and post therapy relapses (4,5). Within the USA and Europe, the 5-year overall survival rate of patients with NSCLC is only 13-17% (6).

Numerous studies have indicated that sex disparities exist in the development and complications of lung cancer (7-16). For instance, Jemal et al (7) reported higher lung cancer susceptibility in young females compared with males in the USA. Possible reasons for this disparity include sex distinctions in genetics and epigenetics (8,9), sex hormone levels (10,11), sex hormone receptors levels (12), post-menopausal hormone replacement therapy (13,14) and smoking history (15,16). Racial and ethnic differences also contribute to the development and complications of lung cancer (17,18).

Izbicka et al (19) used multiplex immunoassays and mass spectrometry to determine the differences in diagnostic biomarkers for sexes in asthma and NSCLC. The results indicated that soluble FAS, matrix metalloproteinase-9 and plasminogen activator inhibitor-1 are strong predictive biomarkers in males, whereas soluble cluster of differentiation 40 was prognostic for cancer in females (19). In another study, Hastings et al (20) found that parathyroid hormone-related protein (PTHrP) is commonly expressed in NSCLC. In female NSCLC subjects, a median survival of 55 and 22 months was observed in those expressing vs. not expressing PTHrP (20). In contrast, an overall 38 months survival in male subjects with NSCLC was observed independent of PTHrP status. These results suggest that PTHrP is a predictor of survival in women, but not men after adjusting for stage and histology of the tumor and age (20).

In non-smokers with NSCLC, biomarkers including epidermal growth factor receptor (EGFR), ELK (Ets like transcription factor-1; highly expressed in NSCLC, irrespective of patient’s age, sex, smoking status and histology) and KRAS mutations are more frequently observed in women compared with men (21,22). These mutations mostly occur in adenocarcinoma (23). Notably, women exhibit greater benefit compared with men when treated with EGFR inhibitors (24). In contrast, women have less benefit from anti programmed death 1 inhibitors compared with men (25). There is no sex distinction in response to ALK (anaplastic lymphoma kinase) inhibitors (26). Of note, ALK inhibitors are anticancer drugs which act on tumours with ALK varied expressions (27). ALK inhibitors are tyrosine kinase inhibitors and act by inhibiting the proteins responsible for abnormal tumour cell growth (28). The higher response rate to anti-EGFR in women may be due to a greater intrinsic EGFR expression (9,29). Notably, female smokers exhibit a higher likelihood of developing lung cancer compared with males (15). The higher female susceptibility to tobacco carcinogens could be due to an enhanced expression of the cytochrome P450 (CYP) enzyme CYP1A, which is responsible for polycyclic aromatic hydrocarbon activation in human lungs (16). Also, female smokers have a higher frequency of TP53 gene mutations compared to non-smoking females or males (30-32). p53, the protein product of TP53, is a potent tumor suppressor (33). Women are also more likely to have mutations in the GSTM1 (Glutathione S-transferase Mu 1) gene, which normally inactivates toxic metabolites and has been linked to lung cancer development in smokers (34). Additional studies are needed in both smokers and non-smokers to fully understand the genetic and epigenetic factors contributing to increased lung cancer incidence in women compared with men.

Physiologically, mammalian lungs are continuously exposed to estrogens by the blood circulation (10). Females produce higher levels of estrogens compared with males, owing to higher aromatase (the enzyme involved in conversion of androgen/testosterone to estrogens) synthesis in gonadal tissues (35-37). Besides major synthesis in the gonads such as ovary, aromatases are locally expressed in non-gonadal tissues including the lungs, brain, liver, bone, intestines, skin, blood vessels and spleen (38,39). Hence, estrogens are synthesized within the lungs normally (40) as well as during various pathologic states including NSCLC (41). Estrogen receptors (ERs: ERα and ERβ) are also detected in lung tissues in the normal physiological state as well as in lung cancers (42,43). While estrogens are normally involved in lung development (44,45), pathophysiologically these hormones serve an important role in lung carcinogenesis and its complications (46-48). At present, a number of clinical trials are ongoing to assess the efficacy of antiestrogen/antiER therapies against NSCLC development and complications (49,50). This approach has been summarized in multiple comprehensive reviews and is therefore not discussed in the present review.

The estrogen related receptors (ERRs) were initially identified from a cDNA library screen by Giguere et al (51). Using rat and human tissue samples, the investigators identified unique clones in kidney and heart cDNA libraries that encoded previously unknown proteins with conserved features of nuclear steroid hormone receptors, particularly ERs (51). The clones were designated as estrogen-related receptor α (ERRα) and estrogen-related receptor β (ERRβ) (51). A third isoform of ERR, ERR-γ (ERRγ) was subsequently identified by Eudy et al (52) through its linkage to the Usher’s Syndrome locus. Hong et al (53) using yeast two-hybrid screening and the nuclear receptor co-activator glutamate receptor-interacting protein 1 as bait also identified ERRγ.

ERRs do not bind endogenous estrogens or their derivatives and are therefore recognized as orphan nuclear receptors, exhibiting considerable structural and functional homology with ERs (Fig. 1) (51). The ERRs involvement in ER-dependent signaling is associated with breast cancer cell proliferation (54). ERRs pathological significance is additionally noted by resistance to tamoxifen, a competitive ER inhibitor used for breast cancer treatment (55) and activity in highly metastatic triple negative (ER, PR, HER) (estrogen, progesterone and human Epidermal growth factor receptor 2 negative) (56). Hence, ERRs appear to serve important pathological roles in both explicitly ER positive and negative breast cancers.

Numerous studies have indicated that ERRs serve pathological roles in other estrogen dependent and independent cancers, including ovarian (57), endometrial (58), prostate (59) colon/colorectal (60) and lung (61). Compounds that modulate ERR activity may serve critical roles in disease progression
as well as homeostasis (62). No endogenous ligand for ERRα has been identified, although several synthetic antagonists have been reported (63-65). Recently, dietary products, such as genistein, apigenin, resveratrol, rutacarpine, piceatanol, daidzein, flavone and cholesterol have been reported as potential ERRα agonists (66-68). The primary aim of the present review is to highlight the emerging role of ERRs in NSCLCs.

2. ERRs and their physiological functions

Giguere et al (51) cloned the first orphan receptors, ERRα and ERRβ, using the ERα DNA-binding domain (DBD) as a probe to screen recombinant DNA libraries. A decade later, Eudy et al (52) identified a third isoform of this family, ERRγ. Based on repetitive genetic analysis, ERRs were grouped into the nuclear receptor 3β family (NR3B) comprising ERRs, PRs, androgens, mineralocorticoids and glucocorticoids (69) (Fig. 1). Genes were identified as responsible for the synthesis of ESRRB (NR3B1, ERRα), ESRRB (NR3B2, ERRβ) and G (NR3B3, ERRγ) (70). Several ERRβ and ERRγ splice variants have been identified that display distinct developmental and tissue specific patterns of expression (70,71). Protein sequence analysis by Laudet et al (72) revealed an ~68% sequence homology within the DBD of ERRs and classical ERs, while there is considerably less homology (~33%) within the ligand binding domain (LBD) (Fig. 2A). Hence, the DBD is more conserved among ERRs and ERs compared with the LBD, suggesting important structural and functional similarities of ERRα and ERRβ (72).

ERRs exhibit structural attributes akin to other nuclear receptors (NRs) (73). Typical functional sites of the overall structure include two activation function domains (AF-1 and AF-2), a DBD and a LBD (73). The N-terminus contains the AF-1 domain, which imparts weak ligand independent transcriptional activation in most NRs (73). Diverging from ERα, the β and γ isoforms share an overall structural relatedness particularly in the N-terminal region (Fig. 2B). This feature is relatively uncommon because of generally poor conservation of the N-terminal region even among receptors of the same subfamily (73). Another significant aspect is the presence of conserved motifs in the N-terminal domain of the 3 ERR isoforms, conditional to the post-translational phosphorylation and sumolation regulated transcriptional events (74,75). The DBDs of ERR comprise 2 strictly conserved zinc finger motifs targeting the receptor to a specific DNA sequence (TCAAGGTCA), which is designated as the ERR response element (ERRE) (73). All 3 members of ERR subfamily have significant similarity in the ERRE domain, suggesting that a number of genes could be targeted by more than one of the ERR isoforms (73). Several reports have demonstrated ERRs binding to ERRE as monomers, homodimers or heterodimers of 2 distinct ERR isoforms (76,77). The extent of ERREs within the ERR complexes of target genes is not known, but it is known to vary significantly based on the cell type, cellular proliferation state and differentiation and in response to organ specific stimuli (73), such as PPARα/sirtuin 1 (Sirt1) complex mediated ERR target suppression in the heart (78), and squamous metaplasia in the prostate gland (79) arising due to altered estrogen synthesis. The affinity of ERRα binding with ERREs is modulated by the extent of acetylation of four lysine residues in the Zn<sup>2+</sup> finger and C-terminal extension of DBD, which is regulated by acetyltransferase F300/CBP-associated factor (PCAF) and deacetylases, histone deacetylase (HDAC8) and SIRT1 (79-81). This deacetylation mechanism is used by HDAC8 and SIRT1 cofactors to link the metabolic status with controlling ERRα target gene selection (80).

The C-terminal LBDs of ERRs have a conserved AF-2 helix motif essential for cofactor interactions (73). A distinctive aspect of ERRs unlike other conventional NRs is their ability to activate transcription without need for exogenous ligands, because the LBD conformation in the absence of ligand supports the involvement of NR co-activators, which are necessary for ER regulated transcriptional activation (82,83). Inspection of the ERRα and ERRγ LBD conformations reveals the importance of amino acids that have bulky side chains occupying the ligand binding pocket, hence mimicking a ligand bound conformation that facilitates cofactor binding (73). As one example, the ERRα LBD crystal structure revealed a significant Phe328 hold of the ligand binding pocket that confers an agonist conformation to the LBD, which further binds the PPARγ co-activator-1α peptide (84). Of note, PPARγ is a type II proton regulating protein encoded by PPARG gene in humans, substantially prevalent in adipose tissue, colon and macrophages (64). While transcriptional activity of ERRs is mostly independent of agonists, structural studies have revealed an open ligand binding pocket of ~220 cubic Å in ERRγ and of ~100 cubic Å in ERRα, allowing transcriptional intervention by synthetic molecules (85-89).

ERRs (ERRα and ERRβ) are members of the steroid/nuclear receptor superfamily and are activated via ligand binding (90). Mammalian ERs function both as signal transducers and transcription factors to modulate target gene expression (91). In response to ligand binding, ERs undergo conformational changes and 'activation', accompanied by heat shock protein hsp90, hsp70 or other proteins dissociations (92), forming a ligand-occupied ER dimer (93). Stimulation of target gene expression in response to 17β-estradiol (E2), or other agonists, is thought to be mediated either via 'direct binding' to DNA specific genes, such as vitellogenin A2 and oxytocin or through 'indirect binding' by transcription factors, such as NF-kB, specificity protein-1 (SP-1) and activator protein-1 (AP-1) (94). In the former, E2-ligated ER dimer (E2-E2-ER) binds directly to a specific estrogen responsive gene sequence, called an estrogen response element (ERE) before interacting with co-activator proteins and RNA polymerase II transcription initiation complex components.
Figure 2. Structural and compositional profile of ERRs. (A) Constitutional binding domains of ERRs. It is notable to observe that DBD and LBD are intervened by a distinctive hinge region, unlike NTD and DBD which interact with each other to a greater extent. Sumoylation refers to post-translational modification effects via ~10 kDa polypeptides. The changes involve formation of isopeptide bonds with ε-amino groups of acceptor Lys residues. The dynamic process (owing to small ubiquitin related modifier (SUMO) specific isopeptidases) is a series of enzyme catalyzed events, involving an activating enzyme (E1), a conjugating enzyme (E2) and in majority of cases, a SUMO ligase (E3). Acetylation is another post-translational modification, wherein a CH$_2$-COOH functional group is introduced to a chemical compound. The characteristic post-translational modifications in NTD (sumoylation) and DBD (acetylation) infer their implicit significance for functional ERR expression. (B) Quantification of constitutional human ERR isoforms, where ERRβ and ERRγ share greater sequence conservation compared with ERRα and ERRβ, corresponding to each domain. PGC-1, proliferator activated receptor-γ co-activator-1; NCoR1, nuclear receptor corepressor 1 (protein encoded by NCoR1 gene in humans); RIP140: Receptor interacting protein 140 (a repressor of androgen receptor); ERRE, ERR response element; Zn, zinc; ERRs, estrogen related receptors.

resulting in enhanced transcription (95). The ERRs are permutations of the 5'-GGTCAnnTGACC-3' DNA palindrome, wherein 'n' denotes a nonspecific 3 nucleotide spacer located at varying distances from the transcription start site and/or within a gene locus (96). The regulation of gene expression by the E2-ER-ER binding to ERRs is referred to as the ER-dependent signaling pathway (97,98). A second mechanism of regulation is the transcriptional modulation of target genes through E2-ER-ER and transcription factors interactions, referred to as 'tethering' (99). The prominent transcription factors involved in this interaction include SPI (100,101), API (102-104), and a number of other proteins (105). In a comprehensive review, Klinge (106) described the molecular mechanism by which ligand bound ER dimers modulate ERR dependent and independent transcription, i.e. transcription factor dependent transcription of various estrogen regulated genes, such as cytochrome c, insulin like growth factor binding protein 4, early estrogen-induced gene 1 and 4, heat shock 70 kDa protein 8, keratin 8 and nuclease sensitive element binding protein 1.

Like ERα, ERRα binds to the classical ERE of estrogen responsive genes, characterized by 5'-AGGTCANNNTGA CCT-3' sequence (N denoting a typical nucleotide) (106). ERRα also has binding sites for an extended half of palindromic ERE as ERR response elements (ERRE), having 5'-TNAAGTCA-3' sequence (91,107,108). Hence, ERRα can affect ERα transcriptional activity. Although ERR dimers can bind to the ERE, ERα dimers (not those of ERβ) also can recognize a functional ERRE, hence demonstrating a nearly identical binding specificity (109).

Basic physiological functions of ERRs include a central role in regulating cellular metabolism by modulating genes involved in glycolysis, the TCA cycle and mitochondrial oxidative phosphorylation (Fig. 3) (110). Normally, an association of proliferator activated receptor γ co-activator 1 (PGC-1) with the ERR transcriptional axis controls mitochondrial biogenesis (111). Besides a role in normal physiology, roles of other PGC-1/ERR pathways are observed in cancers, which depend on tissue specific and environmental stimuli (112-116). For instance, the PGC-1/ERR axis has been identified as necessary for tumor cell motility and metastasis driven malignant transformation in breast and melanoma cancer progression, whereas in prostate cancer the same pathway suppresses tumor progression and metastasis (Table 1) (111,112,117-122).

ERRα is present in tissues actively engaged in high glucose and lipid metabolism including heart, kidney, intestinal tract, skeletal muscles and brown adipose tissues (Fig. 3A) (111,120,122-125). Compared to ERRα, ERRβ and ERRγ expression is much more restricted, with heart and kidney being the major sites (125,126). Expression of both ERRα and ERRγ are increased in preadipocytes and pluripotent mesenchymal cells under adipogenic conditions indicating regulation by lipid accumulation (127,128). In the central nervous system and spinal cord, ERRβ and ERRγ are expressed during early embryonic development (129-131).

Specific roles for each ERR were demonstrated using ERR specific knockout (KO) mice (132-134). ERRα KO mice are viable, but exhibit a phenotype characterized by reduced body weight, peripheral fat deposition and resistance to high-fat diet-induced obesity (132). ERRα KO mice also exhibit cardiac defects in bioenergetics and functional adaptation to pressure overload, but their development and function under normal, unstressed conditions is unaffected (133). ERRα KO mice also exhibit a loss of normal mitochondrial biogenesis (134). In contrast, ERRβ KO mice are lethal due to impaired placenta formation (130). ERRγ KO mice exhibit impaired oxidative phosphorylation of perinatal heart mitochondria resulting in 100% mortality within 48 h of birth (135). In summary, ERRs are essential for maintaining normal physiological functions. While ERRα is detected in the lung, the exact physiologic role of ERRα in the lung is not known. ERRβ and ERRγ have not yet been detected in lung tissues (136).

3. ERRs in NSCLCs

In recent years, several studies have reported a close association between ERRα expression and progression of estrogen-dependent tumors including breast, ovarian, endometrial, prostate and lung cancers as well as non-estrogen-dependent tumors such as gastric, colon and colorectal cancers (47,49-51). This suggests the involvement of ERRα both in estrogen dependent and independent processes for a wide range of tumors (111,137).

Initial studies of various rat and human tissues indicated that high level ERRα expression was a hallmark of metabolically active organs, such as the heart, liver and brain (128,132,134). Low ERRα expression was detected in several other organs including lung (51). Subsequently, using embryonic and adult
mouse tissues, low ERRα levels were demonstrated in bone and skin (138). ERRα has been detected in human NSCLC samples (59). In rats, ERRβ is detected at low levels in kidney, heart, testis, brain and prostate (49), whereas in mouse, it is weakly expressed in adult kidney and heart (139). ERRγ is detected in embryonic lung tissues including humans, but is not detected in adult lungs (71). To the best of our knowledge no study to date, has demonstrated ERRβ and ERRγ expression in adult human lungs.

Regarding the role of ERRα in NSCLC, a number of studies demonstrated elevated ERRα expression in NSCLC cells, xenograft NSCLC mouse models and clinical NSCLC...
Table I. Summary of published studies demonstrating the characteristic effects of ERR in breast, ovarian, prostate, hepatocellular and colorectal cancers.

| First author, year | ERRα | ERRβ | ERRγ | (Refs.) |
|--------------------|------|------|------|---------|
| A, Breast cancer |      |      |      |         |
| Deblois and Giguere, 2013; Gravel, 2018 | • Significantly expressed in all sub-types | • Inversely correlated expression with S-phase fraction: Inhibits cellular proliferation | • Affects the tumor growth via modulating ER expression | (111,112) |
| | • One of the coveted hallmarks and therapeutic target | • A separate study found it as a proliferative gene | • Stimulates E-cadherin activity in ERα negative, HER2 positive and triple negative tumors | |
| | • Strongly active in ERα positive and triple negative tumors | • Thereby, no clarity exists about a possible role in tumor manifestation | • Stimulates bone metastasis of advanced tumors, aggravates estrogen production via sulfotransferase activation: A role linked with conferring resistance to SERM therapy | |
| | • Enhanced ERRα/PGC-1 axis expression is an unfavourable clinical outcome | • Promotes aromatase and c-myc gene expression: Increasing local estrogen production and subsequent malignant transformation of breast epithelium | • Promotes mesenchymal to epithelial transition | |
| | • Serves as transcriptional activator in ER negative tumor cells: competes with estrogen receptors in regulating estrogen responsive genes | • Serves as transcriptional activator in ER negative tumor cells: competes with estrogen receptors in regulating estrogen responsive genes | • AAAG tetranucleotide polymorphism in the untranslated region associated with breast cancer predisposition | |
| | • Stimulates bone metastasis of advanced tumors, aggravates estrogen production via sulfotransferase activation: A role linked with conferring resistance to SERM therapy | • Serves as transcriptional activator in ER negative tumor cells: competes with estrogen receptors in regulating estrogen responsive genes | • Exogenous transfection aggravated tumor proliferation | |
| B, Prostate cancer |      |      |      |         |
| Audet-Walsh et al, 2015 | • Enhanced expression promotes the tumor development: Serves as a vital prognostic factor | • Lowly expressed in developing tumors | • Lowly expressed in developing tumors | (117) |
| | | • Overexpression suppresses the proliferation of androgen sensitive and insensitive tumor cells | • Cancerous lesions and benign foci from radial prostatectomy (after staining and comparing immunoreactive scores) revealed poor expression in tumor tissues | |
| | | • Transactivates a cyclin dependent kinase inhibitor upstream promoter, p21 gene: Inhibited cell cycle progression | • Useful prognostic indicator, though | |
| | | | • Several common attributes with ERRβ | |
### C. Ovarian cancer

| First author, year | ERRα | ERRβ | ERRγ | (Refs.) |
|-------------------|------|------|------|---------|
| Sun et al, 2005   | • ERRα was noticed in all cell lines, with human ERRα (full length cDNA, 2421 bp) and human ERRα-1 (full length cDNA, 2,221 bp) as major isoforms  
• Human ERRα-1 was screened as independent prognostic factor for poor survival with a 95% relative risk | • Human ERRβ-1 (in Mdah-2774 and SKOV-3 cell lines) and human ERR β-2 (in SKOV-3 cell line) were the noted isoforms | • Positive group exhibited a longer progression free survival than ERRγ negative counterparts  
• Noticed in Mdah-2774, OVCAR-3 and SKOV-3 cell lines | (118) |

### D. Gastric cancer

| First author, year | ERRα | ERRβ | ERRγ | (Refs.) |
|-------------------|------|------|------|---------|
| Kang et al, 2018  | • No significant observation reported to date | • No significant observation reported to date | • Recently reported as tumor suppressor using Genomic Analysis approach  
• Both ERRγ and its specific agonist, DY131 inhibited the tumor growth  
• Patients harbouring ERRγ gene signatures revealed improved prognosis  
• Suppresses the transcription of Ant targeting genes (DVL3, LEF1, LGR5, TCF7L2, AXIN2 and CTNNB1) in AGS and MKN28 cells  
• Indirectly influences the β-catenin phosphorylation due to its cytoplasmic location | (119) |

### E. Hepatocellular carcinoma

| First author, year | ERRα | ERRβ | ERRγ | (Refs.) |
|-------------------|------|------|------|---------|
| Kim et al, 2016; Pons et al, 2005 | • No significant correlation with tumor growth was noticed | • No significant correlation with tumor growth was noticed | • Aggravating factor for advanced tumor node metastasis and Barcelona Clinic Liver Cancer Stages | (120,121) |
Table I. Continued.

| First author, year | ERRα | ERRβ | ERRγ | (Refs.) |
|--------------------|------|------|------|---------|
| E, Hepatocellular carcinoma |      |      | • Treatment with siRNA or inverse agonist (GSK5182) inhibited the cell cycle proliferation via G1 arrest, increased p21 and p27 expressions and decreased phosphorylated retinoblastoma protein expressions |      |         |
| F, Colorectal cancer |      |      | • ERRγ inhibitors could serve as potential therapeutic agents |      |         |

Zhou et al, 2019

• Interaction with ovarian tumor domain comprising OTUB1 promoter
• Promotes metastasis via inducing vimentin expression
• OTUB1 could therefore be used as a novel ERRα target

• No significant involvement was noticed
• No significant involvement was noticed (122)

ERR, estrogen related receptor; SERM, selective estrogen receptor modulators; HER-2, human epidermal growth factor receptor 2; OTUB1, ubiquitin aldehyde binding protein I; ER, estrogen; PGC, peroxisome proliferator-activated receptor-γ; CK1, cyclin-dependent kinase inhibitor.
samples, indicating possible diagnostic or post-therapeutic prognostic roles of ERRα in NSCLC (91,138-140). One study elucidated a cell-specific ERRα transactivator functioning though SFRE sequence, wherein ERRα contributed in transcriptional activation in rat osteosarcoma cell line (ROS 17.2/8) and HeLa, NB-E and FREJ4 cells, but not in COS1 and HepG2 cells (138). The investigators reasoned such distinctions in ERRα functioning were due to the osteopontin gene promoter as a transcription regulating target for ERRα (138). Pettersson et al (139) observed the expression of nuclear receptors in embryonal carcinoma stem cells. This study found that adequate homodimerization and DNA binding of mERRβ was exclusively dependent on interaction with heat shock protein 90, a molecular chaperone known to interact exclusively with steroid hormone receptor subgroup of nuclear receptors (140).

In summary, the mouse orphan receptor mERRβ exhibited the potential to control the coinciding gene networks with the estrogen receptor, simultaneously participating in signal transduction pathways during a limited time span analogous to chorion formation (138). Wang et al (140) demonstrated the tumorigenic potential of ERRα via studying the effect of administered XCT-790, an ERRα specific inverse agonist in A549 NSCLC cells. The findings of the aforementioned study revealed reduced mitochondrial mass and enhanced ROS generation through interception of TCA cycle. These changes manifested in elevated mitochondrial membrane potential and suppressed superoxide dismutase expression (140). It was also noticed that XCT-790 modulated the p53 and pRB signaling pathways (via ROS involvement) and consequently suppressed cell replication (140). These observations led to the generalization that disrupting ERRα regulated cell cycle mechanisms could modulate tumour suppressor activities and arrest the cell cycle (140). The specific role of ERRα in NSCLCs has not been determined, but studies have demonstrated its involvement in regulating the cell cycle and cell-extracellular matrix interactions. These observations infer likely ERRα involvement in regulating cell proliferation as well as subsequent invasion/migration (metastasis). The mechanism by which ERRα regulates NSCLC cell division and migration is discussed in the following sections.

4. Role of ERRα in cell cycle regulation and NSCLC proliferation

Continuous cell cycling without a G₂ phase is a characteristic of most cancer cells (141). The basis for continuous cell cycling is the uninterrupted positive stimulatory signals from mitogens, such as growth factors, amino acids (cysteine, histidine and glycine), hormones (estrogens, thyroid hormones and human growth hormone), and cytokines (TNF-α and IL-2) (142,143). These signals are accompanied by suppressed inhibitory signals mediated by tumor suppressor proteins including p21, p27, p53, pRB and PTEN.

NSCLC cell culture-based investigations demonstrated ERRα specific inverse agonists/small interfering (si) RNA/shRNA effect cell cycle regulation (144). In one such investigation using NSCLC A549 cells, Wang et al (140) noticed significant alterations in mitochondrial mass, mitochondrial membrane potential and mitochondrial reactive oxygen species (ROS) generation following the administration of the ERRα inverse agonist XCT-790. The ROS produced by XCT-790 activated the tumor suppressor proteins p53 and pRB, which arrested the cell cycle in NSCLC cells (140). These in vitro cell culture-based observations suggest that in A549 NSCLC cells, ERRα decreases the tumor suppressor proteins p53 and pRB expression by effecting mitochondrial physiology and quenching ROS generation resulting in unopposed cell-cycle progression (Figs. 3A and 4A). Modulation of multiple signaling pathways by ERRα presents implicit cell-division acceleration strategies, which collectively result in tumor progression (Fig. 4B).

In a recent study, Li et al (61) used lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LSCC) cells to study the effects of ERRα knock down. Following ERRα knock down, cell cycle phase (G₁-S-G₂-M) specific distribution of LUAD and LSCC cells were monitored using fluorescence-activated-cell sorting (61). The results demonstrated that ERRα knockdown in LUAD leads to cell synchronization at the G₂-M phase transition, but the LSCC cells continued with cell cycle progression (61). These observations infer that ERRα is essential for LUAD cells G₂-M transition and subsequent cell division, but not for LSCC cells, indicating a cell line specific activity (Figs. 3A and 4A) (61).

5. Role of ERRα in NSCLC invasion and migration

Capacity for invasion and migration remains a hallmark of cancer cell metastasis to distant organs (145). Epithelial to mesenchymal transition (EMT) is an important early step in invasion and metastasis (141,145). In course of acquiring mesenchymal phenotypes, tumor cells progressively develop enhanced motility and the ability to invade through the tumor vasculature (Fig. 5). Acquiring mesenchymal status is an important feature of tumor progression, drug resistance and metastasis (146,147). Several transcription factors are involved in EMT including Snail, Slug, Twist and Zeb (146,148). Notable markers of EMT initiation and progression involve activation of multiple cellular signalling pathways including MAPK, PI3K and pro-inflammatory transcription factors, such as NF-κB (146,149).

In lung cancers, circulating tumour cells expressing epithelial cell adhesion molecules have much lower expression compared with other solid tumours, indicating a loss of epithelial markers (150). The EMT phenotype in NSCLC is associated with EGFR mutations, drug resistance (151-153) and formation of cancer stem cells (154). A number of studies have indicated that EMT related to NSCLC requires immune evasion (155,156).

In lung adenocarcinoma, intratumoral CD8+ Tc (T cytotoxic) cell suppression is mediated through ZEB1, which activates EMT and represses micro RNA-200, an EMT and programmed death ligand-1 suppressor (157).

In an important study, Chae et al (158) analyzed the immune landscape in NSCLCs (adenocarcinoma and squamous cell carcinoma) through EMT scores retrieved from a 16 gene signature of canonical EMT markers (158). Inspection revealed a progressively impaired immune response in cancer, whereby suppressed CD4 T-cells and CD4/CD8-T-cells infiltrations were observed in lung adenocarcinoma and squamous cell carcinoma, respectively (158).

The response was characterized by a considerably decreased
CD4^+ Th cell infiltration in lung adenocarcinoma and of CD4^+CD8^+ Th/Tc cells in squamous cell carcinoma. Additionally, EMT was also found to be associated with enhanced activities of various immunosuppressive cytokines including IL-10 and TGF-β (159,160). The overexpression of targetable immune checkpoint molecules such as CTLA-4 and TIM-3 were noted as being EMT contributory in both NSCLCs. Based on these observations the investigators conclude that immune exclusion and EMT association drive NSCLC characterization (159,160). The EMT phenotype in NSCLC has been demonstrated as critical not only for tumor progression, but also for poor prognosis (161,162). In a recent study, Thompson et al (163) demonstrated the usefulness of an EMT/inflammation signature score in directing checkpoint inhibitor therapy in NSCLC. The results inferred a scenario wherein EMT reversal maybe instrumental in augmenting...
the efficacy of immune checkpoint blockade (163). However, since EMT is a dynamic and highly fluid process, confirmatory studies are needed to ascertain the therapeutic efficacy of EMT inhibitors on NSCLC complications.

Several studies have now reported ERRα involvement in NSCLC EMT. Huang et al (164) treated A549 NSCLC cells with ERRα inverse agonist XCT-790 and examined its effect on markers of epithelial cells, mesenchymal cells and various transcription factors. Analysis revealed ERRα involvement in EMT, as demonstrated by suppression of the epithelial makers, E-cadherin and zonula occludens-1 (noted epithelial markers) and increased fibronectin and vimentin (mesenchymal markers), expression. Zhang et al (165) noticed ERRα aggravated NF-κB expression and translocation which in turn activated the pro-inflammatory cytokine, IL-6 expression. Other studies have reported enhanced IL-6 expression in di (2-ethylhexyl) phthalate (DEHP)-induced NSCLC migration and invasion (166,167). Hence, enhanced ERRα modulates the environment around the tumor by enhanced expression of matrix proteins whereby access of chemotherapeutic drugs to the tumor is prevented, resulting in enhanced tumor growth. ERR, estrogen related receptor; NSCLC, non-small cell lung cancer; EMT, epithelial mesenchymal transition; IL, interleukin.

6. Conclusions and future perspective

While the role of ERs in NSCLC is established, that of ERRs in NSCLC is only beginning to be elucidated. A body of literature has recently developed that suggests an important role of ERRs in the development and progression of various cancers including NSCLCs. In particular, ERRα expression by cancer cells has emerged as an important prognostic indicator associated with poor survival in several cancers including NSCLC (129,130,132). In contrast, the role of ERRβ and ERRγ in NSCLC remains unknown, due to undetectable low level or null expression of these molecules in adult mammalian lungs (133). A number of antiERRα molecules have been developed, including diethylstilbestrol (DES), that bind to ERRα and inhibit its activity (83). At present, most of the studies of the effects of ERRα modulation in NSCLC are based on in vitro cell culture experiments (129-131,162-164). It is now imperative that the molecular mechanisms by which ERRα promotes NSCLC development and progression be examined using in vivo models (137,162-164). The implicit involvement of ERRα in NSCLCs could be screened using ERRα antagonists or activating ERRα dependent signaling pathways using specific agonists. In this age of individualized medicine, the effects of antiERR molecules alone or in combination with aromatase inhibitors (e.g. anastrazole), selective estrogen receptor modulators (SERMs e.g. tamoxifen) or selective estrogen receptor down regulators (SERDs e.g. fulvestrant) should be evaluated in specific NSCLC types.
Acknowledgements

Not applicable.

Funding

The present study was supported by a grant from the Renzetti Presidential Endowed Chair, Department of Internal Medicine, University of Utah, USA.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

TKM conceptualized the basic theme of the manuscript, prepared the first draft of the manuscript and suggested the contents of figures and tables. PM compiled the information about the physiological functions of estrogen related receptors (ERRs) and the specific role of ERRα in cell cycle regulation, NSCLC proliferation and the role of ERRα in NSCLC and migration after discussion and gaining inputs from TKM. TKM and PM addressed the reviewer's comments. JRH participated in manuscript development, particularly in the writing of the lung cancer statistics in males vs. females and the role of epithelial to mesenchymal transition in lung cancer metastasis. JRH also scrutinized, corrected and approved the finalized manuscript in the initial and revised versions. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. International Agency for Research on Cancer (IARC): GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide. 2013.
2. Malvezzi M, Carlioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C and Negri E: Cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol 28: 1117-1123, 2017.
3. Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Yrondi B, Mariotto A, Lake AJ, Wilson R, Sherman RL, et al.: Annual report to the nation on the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst 109: djx030, 2017.
4. Herbst RS, Morgenstern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature 553: 446-454, 2018.
5. Morgenstern D, Ng SH, Gao F and Govindan R: Trends in stage distribution for patients with non-small cell lung cancer: A National cancer database survey. J Thorac Oncol 5: 29-33, 2010.
6. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69: 7-34, 2019.
7. Jemal A, Miller KD, Ma J, Siegel RL, Fedewa SA, Farhaad I, Devesa SS and Thun MJ: Higher lung cancer incidence in young women than young men in the United States. N Engl J Med 379: 1999-2009, 2018.
8. Ragavan MV and Patel MI: Understanding sex disparities in lung cancer incidence: Ar women more at risk? Lung Cancer Manag 9: LMY34, 2020.
9. Yuan Y, Liu L, Chen H, Wang Y, Xu Y, Mao H, Li J, Mills GB, Shu Y, Li L and Liang H: Comprehensive characterization of molecular differences in cancer between male and female patients. Cancer Cell 29: 711-722, 2016.
10. Xia B, Feldman R, Cozen W, Kang I, Raez LE, Borgheihi H, Kim C, Nagasaka M, Mamdani H, Vanderwalde AM, et al.: Sex disparities in hormone positive lung cancer. J Clin Oncol 38 (15_suppl): e21552, 2020.
11. Fidler-Benaoudia MM, Torre LA, Bray F, Ferlay J and Jemal A: Lung cancer incidence in young women vs. young men: A systematic analysis in 40 countries. Int J Cancer 147: 811-819, 2020.
12. Skov BG, Fischer BM and Pappot H: Estrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 59: 88-94, 2008.
13. Greisler CM, Greisler EM and Dören M: Menopausal hormone therapy and risk of lung cancer: Systematic review and meta-analysis. Maturitas 65: 198-204, 2010.
14. Adami HO, Persson I, Hoover R, Schaier C and Bergkvist L: Risk of cancer in women receiving hormone replacement therapy. Int J Cancer 44: 833-839, 1989.
15. Risch HA, Howe GR, Jain M, Burch JD, Holowaty EJ and Miller AB: Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 138: 281-293, 1993.
16. Mollerup S, Berge G, Baera R, Skaug V, Hiever A, Phillips DH, Stangeland L and Haugen A: Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts. Int J Cancer 119: 741-744, 2006.
17. Clugman M, Xue X and Hosgood HD III: Race/ethnicity and lung cancer survival in the United States: A meta-analysis. Cancer Causes Control 30: 1231-1241, 2019.
18. Schabath MB, Cress D and Muñoz-Antonia T: Racial and ethnic differences in the epidemiology and genomics of lung cancer. Cancer Control 23: 338-346, 2016.
19. Ibicka E, Streeper RT, Michalek JE, Louden CL, Diaz A III and Campos DR: Plasma biomarkers distinguish non-small cell lung cancer from asthma and differ in men and women. Cancer Genomics Proteomics 9: 27-35, 2012.
20. Hastings RH, Laux AM, Casillas A, Xu R, Lukas Z, Ernst K and Deftos LJ: Sex-specific survival advantage with parathyroid hormone-related protein in non-small cell lung carcinoma patients. Clin Cancer Res 12: 499-506, 2006.
21. Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, Yang ZY, Mao C and Tang JL: The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget 7: 78985-78993, 2016.
22. Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, et al.: Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 118: 729-739, 2012.
23. Patel MI, McKinley M, Cheng I, Haile R, Wakelee H and Gomez SL: Lung cancer incidence trends in California by race/ethnicity, histology, sex and neighborhood socioeconomic status: An analysis spanning 28 years. Lung Cancer 108: 140-149, 2017.
24. Chang CH, Lee CH, Ho CC, Wang JY and Yu CJ: Sex-based impact of epidermal growth factor receptor mutation in patients with non-small cell lung cancer and previous tuberculosis. Medicine (Baltimore) 94: e444, 2015.
25. Wang C, Qiao W, Jiang Y, Zhu M, Shao J, Ren P, Liu D and Li W: Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer. Cancer Med 8: 4023-4031, 2019.
26. Pinto LA, Vallesjos CS, Raer LE, MaLS LA, RuizR, Torres-RomanJS, Morante Z, Araujo JM, Gomez HL, Aguilar A, et al.: Sex and outcomes in non-small cell lung cancer: An old prognostic variable comes back for targeted therapy and immunotherapy? ESMO Open 3: e000344, 2018.
27. Nelson R: ALK inhibitors: Possible new treatment for lung cancer. Medscape Medical News AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, Jan 15, 2010.
28. Wang WC, Shiao HY, Lee CC, Fung KS and Hsieh HP: Anaplastic lymphoma kinase (ALK) inhibitors: A review of deign and discovery. Med Chem Comm 5: 1266-1279, 2014.

29. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maiekekoop S, Smylie M, Martins R, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132, 2005.

30. Yim SH and Chung YJ: Molecular epidemiology of female lung cancer. Cancers (Basel) 3: 1861-1876, 2011.

31. Guinee DG, Trivedi GE, De Benedetti VM, Cawley W, Welsh JA, Bennett WP, J Colt, TV, Tzelafera H, et al: Sex comparisons in human lung cancer: Analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis 16: 993-1002, 1995.

32. Miller AL, Yeh A, Skagv R, Baer L and Haugen A: p53 mutations in lung tumours: Relationship to sex and lung DNA adduct levels. Carcinogenesis 17: 2201-2205, 1996.

33. Rivlin N, Brosh R, Oren M and Rotter V: Mutations in the p53 tumor suppressor gene. Genes Cancer 2: 466-474, 2011.

34. Rivera MP: Lung cancer in women: Differences in epidemiology, biology, history and treatment outcomes. Semin Respir. Crit Care Med 34: 792-801, 2013.

35. Stocco C: Tissue physiology and pathology of aromatase. Steroids 77: 27-35, 2012.

36. Barakat R, Oakley O, Kim H, Jin J and Ko CJ: Extra-gonadal sites of estrogen biosynthesis and function. BMV Rep 49: 488-496, 2016.

37. Hammes SR and Levin ER: Impact of estrogens in males and androgens in females. J Clin Invest 129: 1818-1826, 2019.

38. Reckhow JF: Sex differences in the regulation of blood pressure and hypertension. J Hypertens 37: 1199-1206, 2019.

39. Blenczk CL, Harvey PA, Reckhow JF and Leinwand LA: The importance of biological sex and estrogen in rodent models of cardiovascular health and disease. Circ Res 118: 1294-1312, 2016.

40. Simpson ER, Clyne C, Rubin G, Boon WC, Robertson K, Britt K, Speed C and Jones M: Aromatase-A brief overview. Ann Rev Physiol 64: 93-127, 2002.

41. Weinberg OK, Marquez-Barcar DC, Fishbein MJ, Goodlick L, Garban HJ, Dubinett SM and Pietras RJ: Aromatase inhibitors in human lung cancer therapy. Cancer Res 65: 11287-11291, 2005.

42. Mollerup S, Jorgensen K, Berge G and Haugen A: Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 37: 153159, 2002.

43. Stabile LP, Davis AL, Gubish CT, Hopkins TM, Luketich JD, Chrissie N, Finkelstein S and Siegfried JM: Human non-smoker lung tissue cells and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62: 2141-2150, 2002.

44. Carey MA, Card JW, Voltz JW, Germolec DR, Korach KS and Zeldin DC: The impact of sex and sex hormones on lung physiology and disease: Lessons from animal studies. Am J Physiol Lung Cell Mol Physiol 293: L272-L277, 2007.

45. Brandenberger AW, Rivlin B, Baer L and Haugen A: Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 37: 153159, 2002.

46. Carey MA, Card JW, Voltz JW, Germolec DR, Korach KS and Zeldin DC: The impact of sex and sex hormones on lung physiology and disease: Lessons from animal studies. Am J Physiol Lung Cell Mol Physiol 293: L272-L277, 2007.

47. Brandenberger AW, Tae MK, Lee JY, Chao V and Jaaffe RB: Tissue distribution of estrogen receptors alpha (ER-alpha) and beta (ER-beta) mRNA in the midgestational human fetus. J Clin Endocrinol Metab 82: 3569-3572, 1997.

48. Márquez-Barcar DC, Chen HW, Fishbein MC, Goodlick L and Pietras RJ: Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 72: 135-143, 2007.

49. Baik CS and Eaton KD: Estrogensignaling in lung cancer: An emerging targets in cancer and metabolic disorders. Curr Top Med Chem 21: 258, 2021.

50. Hong, Yang L and Stallcup MR: Hormone-independent transcriptional activation and coactivator binding by novel orphan nuclear receptor ERER. J Biol Chem 274: 22618-22626, 1999.

51. Latta K and Mukherjee TK: Knockdown of receptor for advanced glycation end products attenuate 17-β-estradiol-stripend dependent proliferation and survival of MCF-7 breast cancer cells. Biochim Biophys Acta 1840: 1083-1091, 2014.

52. Riggins RB, Lan JP, Zhu Y, Klimach U, Zwart A, Cavalli LR, Haddad BR, Chen L, Gong T, Xuan J, et al: ERGamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Res 68: 8908-8917, 2008.

53. Manna S, Bostner J, Sun Y, Miller LD, Alaye A, Schwartz NS, Lager of a tamoxifen response and survival in triple-negative breast cancer. Clin Cancer Res 22: 1425-1438, 2016.

54. Lian S, Mak AS, Tsao SM, Cheung AN, Ngyan HY and Wong AS: Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells. Mol Ther 22: 743-751, 2014.

55. Yoriki K, Mori T, Kokabu T, Matsuhashi H, Umemura S, receptor Y and Kitawaki J: Estrogen-related receptor alpha induces epithelial-mesenchymal transition through cancer-stromal interactions in endometrial cancer. Sci Rep 9: 6697, 2019.

56. Fujimura T, Takahashi S, Urano T, Ijichi N, Ikeda K, Kumagai J, Murata T, Takayama K, Horie-Inoue K, Ouchi Y, et al: Differential expression of estrogen-related receptors beta and gamma (ERRbeta and ERRgamma) in human oral squamous cell carcinoma in human prostate cancer. Cancer Sci 101: 646-651, 2010.

57. Liang R, Lin Y, Yuan CL, Liu ZH, Li YQ, Luo XL, Ye JZ and Ye HH: High expression of estrogen-related receptor α is significantly associated with poor prognosis in patients with colorectal cancer. Oncol Lett 15: 5933-5935, 2018.

58. Li P, Wang J, Wu D, Ren X, Wu W, Zuo R, Zeng Q, Wang B, He X, Yuan J and Xie N: ERαR is an aggressive factor in lung adenocarcinoma indicating poor prognostic outcomes. Cancer Manag Res 11: 8111-8123, 2019.

59. Arts MI, EA and Jordan VC: Estrogen-related receptors as emerging targets in cancer and metabolic disorders. Curr Top Med Chem 20: 203-215, 2006.

60. Busch BB, Stevens WC Jr, Martin R, Ordentlich P, Zhou S, Sapp DW, Horlick RA and Moman R: Identification of a selective inverse agonist for the orphan nuclear receptor estrogen-related alpha. J Med Chem 47: 5593-5596, 2004.

61. Willey PJ, Murray IR, Qian J, Busch BB, Stevens WC Jr, Martin R, Mohan R, Zhou S, Ordentlich P, Wei P, et al: Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ER alphaR) ligand. Proc Natl Acad Sci USA 101: 8912-8917, 2004.

62. Chisamore MJ, Cunningham ME, Flores O, Wilkinson HA and Chen JD: Characterization of a novel small molecule subtype specific estrogen-related receptor alpha antagonist in MCF-7 breast cancer cells. PLoS One 4: e5624, 2009.

63. Teng CT, Beames B, Merrick BA, Martin R, Noyce C and Jetten AM: Development of a stable cell line with an intact PGC-1α/ERαR axis for screening environmental chemicals. Biochem Biophys Res Commun 444: 177-181, 2014.

64. Teng CT, Hsieh JH, Zhao J, Huang R, Xia M, Martin N, Gao X, Dixon D, Auerbach SS, Witt KL and Merrick BA: Development of novel cell lines for high-throughput screening to detect estrogen-related receptor alpha modulators. SLAS Discov 22: 720-731, 2017.

65. Wei W, Schwaid AG, Wang X, Wang X, Chen S, Chu Q, Saghatelian A and Wan Y: Ligand activation of ERαR by cholest erol mediates statin and bisphosphonate effects. Cell Metabol 27: 479-491, 2016.

66. Nuclear Receptors Nomenclature Committee: A unified nomenclature system for the nuclear receptor superfamily. Cell 97: 161-163, 1999.

67. Tremblay AM and Giguere V: The NR3B subgroup: An orphan nuclear receptor superfamily. EMBO J 11: 1003-1004, 1992.
73. Huss JM, Garbacz W and Xie W: Constitutive activities of estrogen related receptors: Transcriptional regulation of metabolism by the ERR pathways in health and disease. Biochim Biophys Acta 1852: 1912-1927, 2015.
74. Tremblay AM, Wilson BJ, Yang XJ and Giguere V: Phosphorylation-dependent sumoylation regulates estrogen-related receptor-alpha and-gamma transcriptional activity through a synergy control motif. Mol Endocrinol 22: 1584-1594, 2008.
75. Vu EH, Kraus RJ and Mertz JE: Phosphorylation-dependent sumoylation of estrogen-related receptor-alpha1. Biochemistry 46: 9795-9804, 2007.
76. Gearhart MD, Hobmcke SM, Evans RM, Dyson HJ and Wright PE: Monomeric complex of human orphan estrogen related receptor-2 with DNA: An ortho-dimer interface mediates extended half-site recognition. J Mol Biol 327: 819-832, 2003.
77. Huppanen J and Aarnisalo P: Dimerisation modulates the activity of the orphan nuclear receptor ERRgamma. Biochem. Biophys Res Commun 314: 964-970, 2004.
78. Oka SI, Zhai P, Alcendorn R, Park JY and Sadoshima J: Suppression of ERR targets by a PPARα/Sirt1 complex in the failing heart. Cell Cycle 11: 856-864, 2012.
79. Onofrio ND, Serrillo L and Balestrieri ML: SIRT1 and SIRT6 signaling pathways in cardiovascular diseases protection. Antioxid Redox Signal 26: 711-732, 2018.
80. Wang C, Fu ZH and Partstall RG: Estrogen receptor acetylation and phosphorylation in hormone responses. Br Cancer Online 8: e46, 2005.
81. Wilson BJ, Tremblay AM, Deblois G, Sylvain-Drolet G and Giguere V: An acetylation switch modulates the transcriptional activity of estrogen-related receptor alpha. Mol Endocrinol 24: 1349-1358, 2010.
82. Chen S, Zhou D, Yang C and Sherman M: Molecular basis for the constitutive activity of estrogen-related receptor alpha1. J Biol Chem 270: 28465-28470, 2000.
83. Wie W, Hong H, Yang NN, Lin RJ, Simon CM, Stallcup MR and Evans RM: Constitutive activation of transcription and binding of coactivator by estrogen-related receptors 1 and 2. Mol Endocrinol 13: 2151-2162, 1999.
84. Kallen J, Schlaeppi JM, Sire A, Schlaeppi J, Strauss A and Fournier B: Evidence for ligand-independent transcriptional activation of the human estrogen-related receptor alpha (ERRalpha): Crystal structure of ERalpha ligand binding domain in complex with peroxisome proliferator-activated receptor-alpha. J Biol Chem 279: 49330-49337, 2004.
85. Greschik H, Flaug R, Renaud JP and Moras D: Structural basis for the deactivation of the estrogen-related receptor gamma by diethylnitrosobenzene or 4-hydroxytamoxifen and determinants of selectivity. J Biol Chem 279: 33639-33646, 2004.
86. Greschik H, Wurtz JM, Sanglier S, Borguet W, van Dorsselaer A, Moig-Noel JP, Strauss A and Fournier B: Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor alpha (ERRalpha): Crystal structure of ERalpha ligand binding domain in complex with peroxisome proliferator-activated receptor-coactivator-alpha1. J Biol Chem 297: 59230-59237, 2004.
87. Wang L, Zuercher WJ, Consler TG, Lambert MH, Miller AB, Orband-Miller LA, McKee DD, Wilson TM and Nolte RT: Small-angle X-ray scattering studies on structures of an estrogen-related receptor ligand binding domain in three functional states reveal the mechanism of estrogen-estrogen receptor signaling. J Biol Chem 282: 23231-23239, 2007.
88. Wang L, Zuercher WJ, Consler TG, Lambert MH, Miller AB, Orband-Miller LA, McKee DD, Wilson TM and Nolte RT: Small-angle X-ray scattering studies on structures of an estrogen-related receptor ligand binding domain in three functional states reveal the mechanism of estrogen-estrogen receptor signaling. J Biol Chem 282: 23231-23239, 2007.
89. Wang L, Zuercher WJ, Consler TG, Lambert MH, Miller AB, Orband-Miller LA, McKee DD, Wilson TM and Nolte RT: Small-angle X-ray scattering studies on structures of an estrogen-related receptor ligand binding domain in three functional states reveal the mechanism of estrogen-estrogen receptor signaling. J Biol Chem 282: 23231-23239, 2007.
An epithelial-mesenchymal transition is associated with a distinct cell population in prostate cancer metastasis. Nat Cell Biol 19: 1029-1039, 2017.

115. Torrano V, Valcarcel-Jimenez L, Cortazar AR, Liu X, Urosevic J, Castillo-Martin M, Fernandez-Ruiz S, Morciano G, Caro-Maldonado A, Guim M, et al.: The metabolic co-regulator PGC-1α suppresses prostate cancer metastasis. Nat Cell Biol 18: 645-656, 2016.

116. Deblois G, St-Pierre J and Giguere V: The PGC-1/ERR signaling axis in cancer. Oncogene 32: 3483-3490, 2013.

117. Auert-Walsh E, Yee T, McGuirk S, Vernier M, Ouellet C, St-Pierre J and Giguere V: Androgen-dependent repression of ERR-alpha in the prostate. J Steroid Biochem Mol Biol 91: 569-579, 2006.

118. Lubahn DB: Identification and characterization of two novel estrogen receptors, a subfamily of orphan nuclear receptors, as new tumor suppressors. J Mol Med 85: 457-467, 2007.

119. Wang X, Liu Z, Wu J, Liu JH, Hyder SM, Antoniou E and Chen D: ERRalpha: A metabolic function for the oldest orphan. Trends Endocrinol Metab 19: 269-276, 2008.

120. Zhou W, Liu Z, Wu J, Liu JH, Hyder SM, Antoniou E and Chen D: ERRgamma directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab 6: 13-24, 2007.

121. Jonker JW, Giles W, Naviaux RK, Giguere V and Evans RM: Estrogen-related receptor gamma in the nervous system during mouse embryo development. Biochim Biophys Acta 1789:71-77, 2009.

122. Inoue S: Modulation of adipogenesis-related gene expression by estrogen-related receptor gamma during adipocytic differentiation. Mol Cell Biol 25: 656-658, 2005.

123. Kubo M, Iijichi N, Ikeda K, Horie-Inoue K, Takeda S and Inoue S: Estrogen-related receptor alpha modulates the expression of adipogenesis-related genes during adipocyte differentiation. Biochem Biophys Res Commun 358: 814-818, 2007.

124. Luo C, Balasa E, Thomas A, Hatting M, Jedrychowski M, Gyu SP, Fudiling HR and Puigserver P: ERR alpha maintains mitochondrial oxidative metabolism and constitutes an actionable target in PGC1α-elevated melanomas. Mol Cancer Res 15: 1366-1375, 2017.

125. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM and Mangelsdorf DJ: Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126: 789-799, 2006.

126. Ranhotra HS: The orphan estrogen-related alpha and beta receptors, a subfamily of orphan nuclear receptors, as new tumor suppressors. J Mol Med 85: 457-467, 2007.

127. Iijichi N, Ikeda K, Horie-Inoue K, Yagi K, Okazaki Y and Inoue S: Estrogen-related receptor alpha regulates mitochondrial oxidative metabolism and constitutes an actional target in PGC1α-elevated melanomas. Mol Cancer Res 15: 1366-1375, 2017.

128. Iijichi N, Ikeda K, Horie-Inoue K, Takeda S and Inoue S: Modulation of adipogenesis-related gene expression by estrogen-related receptor gamma during adipocytic differentiation. Mol Cell Biol 25: 656-658, 2005.

129. Giguère V: Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev 29: 677-696, 2008.

130. Iijichi N, Ikeda K, Horie-Inoue K, Yagi K, Okazaki Y and Inoue S: Estrogen-related receptor alpha modulates the expression of adipogenesis-related genes during adipocyte differentiation. Biochem Biophys Res Commun 358: 814-818, 2007.

131. Kubo M, Iijichi N, Ikeda K, Horie-Inoue K, Takeda S and Inoue S: Modulation of adipogenesis-related gene expression by estrogen-related receptor gamma during adipocytic differentiation. Biochim Biophys Acta 1789:71-77, 2009.

132. Lacroix DJ, St-Pierre U and Harnans-Borgmeyer I: Differential expression of the estrogen receptor related receptor gamma in the mouse brain. Brain Res Mol Brain Res 77: 277-280, 2000.

133. Luo J, Sladek R, Bader JA, Matthyssen A, Rossant J and Evans RM: Estrogen-related receptor alpha and beta receptors, a subfamily of orphan nuclear receptors, as new tumor suppressors. J Mol Med 85: 457-467, 2007.

134. Baker WS, Kondo RP, Xie W, He W, Dufour C, Downes M, Jonker JW, Giles W, Navaiaux RK, Giguere V and Evans RM: ERRalpha directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab 6: 13-24, 2007.

135. Zhou W, Liu Z, Wu J, Liu JH, Hyder SM, Antoniou E and Chen D: ERRalpha: A metabolic function for the oldest orphan. Trends Endocrinol Metab 19: 269-276, 2008.

136. Alaynick WA, Kondo RP, Xie W, He W, Dufour C, Downes M, Jonker JW, Giles W, Navaiaux RK, Giguere V and Evans RM: ERRgamma directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab 6: 13-24, 2007.

137. Zhou W, Liu Z, Wu J, Liu JH, Hyder SM, Antoniou E and Chen D: ERRalpha: A metabolic function for the oldest orphan. Trends Endocrinol Metab 19: 269-276, 2008.

138. Alaynick WA, Kondo RP, Xie W, He W, Dufour C, Downes M, Jonker JW, Giles W, Navaiaux RK, Giguere V and Evans RM: ERRgamma directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab 6: 13-24, 2007.

139. Zhou W, Liu Z, Wu J, Liu JH, Hyder SM, Antoniou E and Chen D: ERRalpha: A metabolic function for the oldest orphan. Trends Endocrinol Metab 19: 269-276, 2008.

140. Alaynick WA, Kondo RP, Xie W, He W, Dufour C, Downes M, Jonker JW, Giles W, Navaiaux RK, Giguere V and Evans RM: ERRgamma directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab 6: 13-24, 2007.

141. Zhou W, Liu Z, Wu J, Liu JH, Hyder SM, Antoniou E and Chen D: ERRalpha: A metabolic function for the oldest orphan. Trends Endocrinol Metab 19: 269-276, 2008.

142. Alaynick WA, Kondo RP, Xie W, He W, Dufour C, Downes M, Jonker JW, Giles W, Navaiaux RK, Giguere V and Evans RM: ERRgamma directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab 6: 13-24, 2007.

143. Zhou W, Liu Z, Wu J, Liu JH, Hyder SM, Antoniou E and Chen D: ERRalpha: A metabolic function for the oldest orphan. Trends Endocrinol Metab 19: 269-276, 2008.

144. Alaynick WA, Kondo RP, Xie W, He W, Dufour C, Downes M, Jonker JW, Giles W, Navaiaux RK, Giguere V and Evans RM: ERRgamma directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab 6: 13-24, 2007.

145. Zhou W, Liu Z, Wu J, Liu JH, Hyder SM, Antoniou E and Chen D: ERRalpha: A metabolic function for the oldest orphan. Trends Endocrinol Metab 19: 269-276, 2008.

146. Alaynick WA, Kondo RP, Xie W, He W, Dufour C, Downes M, Jonker JW, Giles W, Navaiaux RK, Giguere V and Evans RM: ERRgamma directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab 6: 13-24, 2007.

147. Zhou W, Liu Z, Wu J, Liu JH, Hyder SM, Antoniou E and Chen D: ERRalpha: A metabolic function for the oldest orphan. Trends Endocrinol Metab 19: 269-276, 2008.

148. Alaynick WA, Kondo RP, Xie W, He W, Dufour C, Downes M, Jonker JW, Giles W, Navaiaux RK, Giguere V and Evans RM: ERRgamma directs and maintains the transition to oxidative metabolism in the postnatal heart. Cell Metab 6: 13-24, 2007.

149. Zhou W, Liu Z, Wu J, Liu JH, Hyder SM, Antoniou E and Chen D: ERRalpha: A metabolic function for the oldest orphan. Trends Endocrinol Metab 19: 269-276, 2008.
158. Chae YK, Chang S, Ko T, Anker J, Agte S, Iams W, Choi WM, Lee K and Cruz M: Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). Sci Rep 8: 2918, 2018.

159. Kwaśniak K, Czarnik-Kwaśniak J, Maziarz A, Aebisher D, Zielińska K, Karczmarek-Borowska B and Tabarkiewicz J: Scientific reports concerning the impact of interleukin 4, interleukin 10 and transforming growth factor β on cancer cells. Cent Eur J Immunol 44: 190-220, 2019.

160. Steen EH, Wang X, Balaji S, Butte MJ, Bollyky PL and Keswani SG: The role of the anti-inflammatory cytokine Interleukn-10 in tissue fibrosis. Adv Wound Care (New Rochelle) 9: 184-198, 2020.

161. Tsoukalas N, Aravantinou-Fatorou A, Tolia M, Giaginis C, Galanopoulos M, Kikou M, Kostakis ID, Dana E, Vamvakaris I, Korogiannis A, et al.: Epithelial-mesenchymal transition in non small-cell lung cancer. Anticancer Res 37: 1773-1778, 2017.

162. Mahmood MQ, Ward C, Muller HK, Sohal SS and Walters EH: Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): A mutual association with airway disease. Med Oncol 34: 45, 2017.

163. Thompson JC, Hwang WT, Davis C, Deshpande C, Jeffries S, Rajpurohit Y, Krishna V, Smirnov D, Verona R, Lorenzi MV, et al.: Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Lung Cancer 139: 1-8, 2020.

164. Huang JW, Guan BZ, Yin LH, Liu FN, Hu B, Zheng QY, Li FL, Zhong YX and Chen Y: Effects of estrogen-related receptor alpha (ERRα) on proliferation and metastasis of human lung cancer A549 cells. J Huazhong Univ Sci Technolog Med Sci 34: 875-881, 2014.

165. Zhang J, Guan X, Liang N and Li S: Estrogen-related receptor alpha triggers the proliferation and migration of human non-small cell lung cancer via interleukin-6. Cell Biochem Funct 36: 255-262, 2018.

166. Wang Y, Zhao M, Liu J, Ni J, Jiao Y and Bai C: Up regulation of IL-6 is involved in di (2-ethylhexyl) phthalate (DEHP) induced migration and invasion of non-small cell lung cancer (NSCLC) cells. Biomed. Pharmacother 89: 1037-1044, 2017.

167. Kim JH: Di(2-ethylhexyl) phthalate promotes lung cancer cell line A549 progression via Wnt/β-catenin signaling. J Toxicol Sci 44: 237-244, 2019.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.